|
|
Vaccine Detail
|
Francisella tularensis capB mutant vaccine |
| Vaccine Information |
- Vaccine Name: Francisella tularensis capB mutant vaccine
- Target Pathogen: Francisella tularensis
- Target Disease: Tularemia
- Vaccine Ontology ID: VO_0002840
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- capB
gene engineering:
- Type: Gene mutation
- Description: This capB mutant is from Francisella tularensis (Jia et al., 2010).
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
|
| Host Response |
|
Mouse Response
- Persistence: A capB mutant is attenuated in mice (Jia et al., 2010).
- Efficacy: A capB mutant induces significant protection in mice from challenge with wild type F. tularensis (Jia et al., 2010).
- Host IgG response
- Description: Following i.n. immunization, LVS ΔcapB induced significantly higher levels of serum IgG, IgG2a, and IgM antibodies in mice than LVS by 7 days post immunization (Jia et al., 2010).
- Detailed Gene Information: Click Here.
- Host Ighv1-9 response
- Description: Following i.n. immunization, LVS ΔcapB induced significantly higher levels of serum IgG, IgG2a, and IgM antibodies in mice than LVS by 7 days post immunization (Jia et al., 2010).
- Detailed Gene Information: Click Here.
- Host IgM response
- Description: Following i.n. immunization, LVS ΔcapB induced significantly higher levels of serum IgG, IgG2a, and IgM antibodies in mice than LVS by 7 days post immunization (Jia et al., 2010).
- Detailed Gene Information: Click Here.
|
| References |
Jia et al., 2010: Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infection and immunity. 2010; 78(10); 4341-4355. [PubMed: 20643859].
|
|
